16 June 2021 - But only rich countries will benefit, and even they will struggle to get hold of it.
An antibody medicine from Regeneron, a firm in upstate New York, improves the survival of patients with COVID-19 and offers renewed hope for the treatment of those most seriously ill with the disease.
A study in British hospitals found that Regen-Cov saved the lives of many of those unable to make their own antibodies in response to SARS-CoV-2. Such “seronegative” individuals constituted about a third of the 9,785 hospital patients in the study.